ORAGENICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ORAGENICS, INC. (OGEN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of -$86.62 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was -$147.00, a 100.25% decline year-over-year.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was -$86.47K, a 224.70% decline year-over-year.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $330.80K.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $58.22K, a 8.50% decline year-over-year.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was -$86.62K, a 116.78% decline from fiscal 2024.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $516.05K, a 6.19% decline from fiscal 2023.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $550.08K, a 25.89% decline from fiscal 2022.
- ORAGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $742.20K, a 56.03% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$86.62K 10-K · filed 2026-03-16 | |||
| 2025-06-30 | -$147.00 10-Q · filed 2026-08-13 | -$86.62K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$86.47K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $516.05K 10-K · filed 2025-03-14 | |||
| 2024-09-30 | $330.80K 10-Q · filed 2024-11-13 | $389.02K derived: sum of 2 quarters · filed 2024-11-13 | $458.37K derived: sum of 3 quarters · filed 2025-05-09 | |
| 2024-06-30 | $58.22K 10-Q · filed 2024-11-13 | $127.56K derived: sum of 2 quarters · filed 2025-05-09 | ||
| 2024-03-31 | $69.34K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $550.08K 10-K · filed 2025-03-14 | |||
| 2023-09-30 | -$1.59K 10-Q · filed 2024-11-13 | $62.04K derived: sum of 2 quarters · filed 2024-11-13 | $142.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $63.63K 10-Q · filed 2024-11-13 | $143.59K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $79.97K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $742.20K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $468.55K 10-Q · filed 2023-11-09 | $747.53K derived: sum of 2 quarters · filed 2023-11-09 | $837.78K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $278.99K 10-Q · filed 2023-11-09 | $369.24K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $90.25K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $1.69M 10-K · filed 2023-04-17 | |||
| 2021-09-30 | $100.77K 10-Q/A · filed 2023-04-14 | $331.91K derived: sum of 2 quarters · filed 2023-04-14 | $1.46M derived: sum of 3 quarters · filed 2023-04-14 | |
| 2021-06-30 | $231.14K 10-Q/A · filed 2023-04-14 | $1.35M derived: sum of 2 quarters · filed 2023-04-14 | ||
| 2021-03-31 | $1.12M 10-Q/A · filed 2023-04-14 | |||
| 2020-12-31 | $1.49M 10-K/A · filed 2022-07-29 | |||
| 2020-09-30 | $194.95K 10-Q · filed 2021-11-15 | $352.10K derived: sum of 2 quarters · filed 2021-11-15 | $1.22M derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $157.15K 10-Q · filed 2021-11-15 | $1.02M derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $865.11K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $553.00K 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $232.18K 10-Q · filed 2020-11-10 | $396.76K derived: sum of 2 quarters · filed 2020-11-10 | $542.59K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $164.59K 10-Q · filed 2020-11-10 | $310.42K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $145.83K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $996.04K 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |